Systemic Lupus Erythematosus Pipeline Summary

DelveInsight’s, “Systemic Lupus Erythematosus Pipeline Insight, 2026” report provides comprehensive insights about 120+ companies and 140+ pipeline drugs in Systemic Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Systemic Lupus Erythematosus Understanding

Systemic Lupus Erythematosus Overview

According to the American College of Rheumatology, Systemic Lupus Erythematosus (SLE), or lupus, is a chronic autoimmune disease marked by systemic inflammation that can affect multiple organs, including the skin, joints, kidneys, lungs, heart, and brain, with symptoms such as fatigue, fever, and weight loss, and a course characterized by alternating periods of flare-ups and remission. Pathologically, SLE is defined by inflammation, vasculitis, immune complex deposition, and vasculopathy, with lupus nephritis representing a particularly severe complication that involves inflammation of renal microvasculature and contributes significantly to morbidity and mortality. The disease most commonly occurs in women of reproductive age, though it is increasingly recognized in individuals over 40, especially among Europeans, and is associated with relapsing activity that can lead to cumulative organ damage and increased risk of premature death, primarily from infections and cardiovascular disease. Clinical manifestations are highly variable and may include joint pain, muscle weakness, fever, malaise, and involvement of multiple organ systems such as the skin, kidneys, lungs, central nervous system, and hematopoietic system. Advances in immunological research highlight the roles of dysregulated T and B lymphocytes, innate immune abnormalities, and tissue-specific damage, with SLE characterized by polyclonal B-cell activation, altered memory B-cell subsets, and impaired immune regulation. Key inflammatory mediators, including BLyS, interleukins (IL-6, IL-17, IL-18), type I interferons, and TNF-α, are central to disease pathogenesis and represent important therapeutic targets.

Lupus is an autoimmune disease in which the immune system attacks healthy tissues, driven by a combination of genetic predisposition and environmental triggers, though the exact cause is often unknown. Triggers may include sunlight, infections, and certain medications such as procainamide, hydralazine, minocycline, phenytoin, and isoniazid, which can cause drug-induced lupus that usually resolves after stopping the drug. Risk factors for Systemic Lupus Erythematosus include female sex, age 15–44 years, certain ethnic backgrounds (including African American, Hispanic/Latino, Asian, Native American, and Pacific Islander populations), and a family history of the disease, which increases susceptibility but does not guarantee development.

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with highly variable presentation, affecting nearly any organ system and characterized by alternating flares and remissions. Common symptoms include fatigue, fever, joint pain or arthritis, skin rash, oral ulcers, and hair loss, while more severe cases may involve the kidneys, heart, lungs, blood cells, or nervous system. Childhood-onset SLE more often presents with features such as malar rash, mucocutaneous lesions, renal involvement (proteinuria and urinary casts), seizures, cytopenias, fever, and lymphadenopathy, whereas adults more commonly experience Raynaud phenomenon, pleuritis, and sicca symptoms. Overall manifestations span multiple systems, including musculoskeletal, dermatologic, renal, neuropsychiatric, pulmonary, gastrointestinal, cardiac, and hematologic involvement, with a classic triad of fever, arthritis, and rash in women of childbearing age strongly suggestive of the disease.
Systemic Lupus Erythematosus is a multisystem inflammatory autoimmune disease with highly variable presentation, commonly affecting the skin, joints, kidneys, lungs, CNS, and blood system, and often difficult to diagnose early due to nonspecific symptoms like fatigue, fever, rash, and arthralgia along with initially normal laboratory markers. Diagnosis is based on clinical evaluation supported by immunological testing, with the ACR criteria remaining the diagnostic standard, while SLICC criteria offer higher sensitivity but lower specificity and require a combination of clinical and immunologic features or biopsy-proven lupus nephritis with positive serology. Recommended investigations include CBC, CMP, ESR, CRP, ANA profile, anti-dsDNA, extractable nuclear antigens, complement levels, and urinalysis, alongside screening for infections and comorbidities relevant to immunosuppressive therapy; antiphospholipid antibodies are also assessed due to thrombotic and obstetric risks. Further imaging or tissue biopsy is guided by clinical need, and evaluation for overlap conditions such as Sjögren’s syndrome may require additional serology or biopsy when indicated.

Systemic Lupus Erythematosus has no cure, but it is effectively managed with a stepwise approach tailored to disease severity and organ involvement, aiming to control inflammation, prevent flares, and reduce long-term damage. Mild disease is typically treated with NSAIDs and antimalarials (especially hydroxychloroquine), while moderate to severe or organ-threatening disease requires glucocorticoids and immunosuppressants such as methotrexate, azathioprine, cyclophosphamide, or mycophenolate mofetil. NSAIDs mainly relieve pain and fever but carry risks of gastrointestinal, renal, and cardiovascular toxicity, whereas antimalarials are central to long-term control and flare prevention but require eye monitoring due to rare retinal toxicity. Glucocorticoids provide rapid symptom control with dosing adjusted to severity, though long-term use is limited by significant systemic side effects. Biologic therapies such as belimumab and rituximab are used in refractory cases to target B-cell–mediated disease, while intravenous immunoglobulin may be used selectively for immunomodulation. Overall management is individualized by organ involvement and includes supportive care, infection screening, and ongoing monitoring for treatment toxicity and disease progression.

"Systemic Lupus Erythematosus Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Systemic Lupus Erythematosus pipeline landscape is provided which includes the disease overview and Systemic Lupus Erythematosus treatment guidelines. The assessment part of the report embraces, in depth Systemic Lupus Erythematosus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Lupus Erythematosus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Systemic Lupus Erythematosus Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Lupus Erythematosus R&D. The therapies under development are focused on novel approaches to treat/improve Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus Emerging Drugs Analysis

This segment of the Systemic Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Systemic Lupus Erythematosus Emerging Drugs 

Obinutuzumab: Roche

GAZYVA/GAZYVARO (obinutuzumab) injection, for IV use, is an engineered monoclonal antibody that targets a protein called CD20 on the surface of the lymphoma and leukemia cells. It binds to Type 2 CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependent cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies. Upon binding to CD20, it mediates B-cell lysis through the engagement of immune effector cells by directly activating intracellular death signaling pathways and/or activation of the complement cascade. GAZYVA is marketed as GAZYVARO in Europe. Currently, the drug is registered for the treatment of Systemic Lupus Erythematosus.

BIIB-059: Biogen

BIIB059, discovered and developed exclusively by Biogen, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of SLE. BDCA2 is a receptor that is exclusively expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs), and it has been shown to reduce inflammatory cytokine production from pDCs, including type-I IFN (IFN-I). Inflammatory mediators are thought to play a major role in the pathogenesis of lupus. The drug has successfully completed Phase II and is currently in Phase III for SLE.

Ianalumab: Novartis Pharmaceuticals

Ianalumab is a subcutaneously administered fully human HuCAL antibody that targets BAFF-R and is being investigated by Novartis for the treatment of autoimmune hepatitis, idiopathic pulmonary fibrosis, SLE, and lupus nephritis. It is an anti-BAFF receptor, fully human monoclonal antibody engineered for direct ADCC-mediated B-cell depletion. The drug is currently in Phase III stage of its clinical development for the treatment of SLE.

Nipocalimab: Johnson & Johnson

Nipocalimab (M281) is a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn monoclonal antibody. In patients with gMG, nipocalimab is expected to improve nerve-to-muscle signals and muscle function, thus alleviating the clinical signs and symptoms of gMG. The drug is currently in phase III stage of development for the treatment of Systemic Lupus Erythematosus.

SAR441344: Sanofi

Frexalimab (SAR441344) is an anti-CD40L mAb being developed in collaboration with ImmuNext. Frexalimab targets the CD40–CD40L pathway, a key regulator of immune system activation. It is designed to modulate T-cell and B-cell interactions without broadly suppressing the immune system. By inhibiting this pathway, frexalimab aims to reduce inflammation and autoimmune activity. The drug is being explored for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). Currently, the drug is in Phase II for the treatment of Systemic Lupus Erythematosus.

VIS171: Otsuka Pharmaceuticals

VIS171 is a modified interleukin-2 (mIL-2) molecule engineered to selectively activate and expand regulatory T cells (Tregs). It is currently in Phase I clinical development, with trials aimed at evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy subjects and those with autoimmune diseases including SLE.

AB-101: Artiva Biotherapeutics

AB-101, also known as AlloNK, is an innovative therapy currently under investigation for treating lupus nephritis, a severe kidney complication associated with systemic lupus erythematosus (SLE). This therapy utilizes allogeneic natural killer (NK) cells, which are a type of immune cell that can enhance the effectiveness of monoclonal antibody treatments. Currently, the drug is in the Phase I stage of its development for the treatment of Systemic Lupus Erythematosus.

GRI-0803: GRI Bio

GRI-0803 is an investigational small-molecule therapy developed by GRI Bio for the treatment of Systemic Lupus Erythematosus (SLE), currently in preclinical to early clinical development. It is designed as an oral activator of type 2 natural killer T (NKT) cells, which helps modulate immune responses by suppressing pro-inflammatory pathways, reducing cytokines (such as IL-6 and IL-17), and decreasing autoantibody production. In preclinical lupus models, GRI-0803 has demonstrated inhibition of lupus nephritis, reduction in proteinuria and renal inflammation, and improved survival outcomes. The drug is aimed at targeting upstream immune dysregulation to slow disease progression rather than simply controlling symptoms, positioning it as a potential disease-modifying therapy in SLE. Currently, the drug is in Preclinical Stage of its development for the treatment of Systemic Lupus Erythematosus.

Further product details are provided in the report……..

Systemic Lupus Erythematosus Drug Therapeutic Assessment

This segment of the report provides insights about the different Systemic Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:

Major Systemic Lupus Erythematosus Players in Systemic Lupus Erythematosus

There are approx. 120+ key companies which are developing the therapies for Systemic Lupus Erythematosus. The companies which have their Systemic Lupus Erythematosus drug candidates in the most advanced stage, i.e. Registration include, Roche.

Systemic Lupus Erythematosus Clinical Trial Phases

DelveInsight’s report covers around 140+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Systemic Lupus Erythematosus Drug Route of Administration

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Systemic Lupus Erythematosus Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Systemic Lupus Erythematosus Product Type

• Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Systemic Lupus Erythematosus Clinical Trial Activities 

The Systemic Lupus Erythematosus pipeline report provides insights into different Systemic Lupus Erythematosus Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Systemic Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.

Systemic Lupus Erythematosus Pipeline Development Activities

The Systemic Lupus Erythematosus Clinical Trial report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Systemic Lupus Erythematosus drugs.

Systemic Lupus Erythematosus Pipeline Report Insights

• Systemic Lupus Erythematosus Pipeline Analysis
• Systemic Lupus Erythematosus Therapeutic Assessment
• Systemic Lupus Erythematosus Unmet Needs
• Impact of Systemic Lupus Erythematosus Drugs

Systemic Lupus Erythematosus Pipeline Report Assessment

• Systemic Lupus Erythematosus Pipeline Product Profiles
• Systemic Lupus Erythematosus Therapeutic Assessment
• Systemic Lupus Erythematosus Pipeline Assessment
• Systemic Lupus Erythematosus Inactive drugs assessment
• Systemic Lupus Erythematosus Market Unmet Needs

Key Questions Answered in the Systemic Lupus Erythematosus Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Systemic Lupus Erythematosus drugs?
• How many Systemic Lupus Erythematosus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Lupus Erythematosus?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Systemic Lupus Erythematosus therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Systemic Lupus Erythematosus and their status?
• What are the key designations that have been granted to the emerging drugs?

Systemic Lupus Erythematosus Key Players

• AbbVie
• Beijing InnoCare Pharma Tech Co., Ltd.
• Alumis Inc.
• Galapagos NV
• Palleon Pharmaceuticals
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Amgen
• Johnson & Johnson
• Novartis
• Sanofi
• Merck KGaA
• Resolve Therapeutics
• ILTOO Pharma
• Roche
• Eisai 
• Vertex Pharmaceuticals
• Kyverna Therapeutics
• Miltenyi Biomedicine
• Astrazeneca
• Century Therapeutics
• Daiichi Sankyo Company
• Nanjing Immunophage Biotech
• Cabaletta Bio
• Ascentage Pharma
• AstraZeneca
• Excyte Biopharma
• Sunshine Guojian Pharmaceutical
• Sinocelltech
• Otsuka Pharmaceutical
• GRI Bio

Systemic Lupus Erythematosus Key Products

• ABBV-599
• ICP-022
• ESK-001
• GLPG3667
• HLX79
• TQB3702
• Inebilizumab + Blinatumomab
• Nipocalimab
• Iptacopan
• SAR441344
• Enpatoran
• RSLV-132
• Aldesleukin
• Obinutuzumab
• E6742
• ALPN-303
• KYV-101
• MB-CART19.1
• AZD0120
• CNTY-101
• DS-7011a
• IPG11406
• CABA-201
• APG-2575
• AZD0120
• YK012
• SSGJ 626
• SCTB 35
• VIS171
• GRI-0803